Autolus Therapeutics Selects Cardinal Health as U.S. Commercial Distribution Partner
April 27, 2023 at 07:00 AM EDT
LONDON, April 27, 2023 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced it has selected Cardinal Health Inc. (NYSE: CAH) to support the launch and commercialization of its CAR T-cell therapies in the United States, subject to FDA approval.
Under the proposed agreement, Cardinal Health 3PL Services will establish essential capabilities for Autolus to commercialize a CAR T-cell therapy in the U.S., including a depot model that allows Autolus to maintain custody and physically position product closer to treatment sites during finalization of product release, with the goal of shortening vein-to-delivery times. In addition, Cardinal Health will help provide seamless order-to-cash capabilities.
“We are delighted to have selected Cardinal Health, an established leader in providing core services needed to commercialize CAR T-cell therapy, in the U.S.,” said Christopher Vann, SVP, Chief Operating Officer of Autolus. “This selection is an important milestone in the preparation for the commercialization of obe-cel. We look forward to presenting the primary data from the FELIX study at ASCO and EHA in June and are planning to file for a BLA with the FDA by the end of 2023.”
“We are very excited to partner with Autolus to provide order to cash management and our unique depot model to store their obe-cel,” said Joel Wayment, Vice President, Cardinal Health 3PL Services. “This collaboration will accelerate speed to market, ensuring that patients have more timely access to therapy.”
About Autolus Therapeutics plc
About Cardinal Health
About obe-cel (AUTO1)
About obe-cel FELIX clinical trial
Susan A. Noonan